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Abstract 
Background: The use of 18F-FDG PET–CT (PET–CT) is widespread in many cancer types compared to sarcoma. We 
report a large retrospective audit of PET–CT in bone and soft tissue sarcoma with varied grade in a single multi-disci-
plinary centre. We also sought to answer three questions. Firstly, the correlation between sarcoma sub-type and grade 
with 18FDG SUVmax, secondly, the practical uses of PET–CT in the clinical setting of staging (during initial diagnosis), 
restaging (new baseline prior to definitive intervention) and treatment response. Finally, we also attempted to evalu-
ate the potential additional benefit of PET–CT over concurrent conventional CT and MRI.
Methods: A total of 957 consecutive PET–CT scans were performed in a single supra-regional centre in 493 sarcoma 
patients (excluding GIST) between 2007 and 2014. We compared, PET–CT SUVmax values in relation to histology and 
FNCCC grading. We compared PET–CT findings relative to concurrent conventional imaging (MRI and CT) in staging, 
restaging and treatment responses.
Results: High-grade (II/III) bone and soft tissue sarcoma correlated with high SUVmax, especially undifferentiated ple-
omorphic sarcoma, leiomyosarcoma, translocation induced sarcomas (Ewing, synovial, alveolar rhabdomyosarcoma), 
de-differentiated liposarcoma and osteosarcoma. Lower SUVmax values were observed in sarcomas of low histologi-
cal grade (grade I), and in rare subtypes of intermediate grade soft tissue sarcoma (e.g. alveolar soft part sarcoma and 
solitary fibrous tumour). SUVmax variation was noted in malignant peripheral nerve sheath tumours, compared to the 
histologically benign plexiform neurofibroma, whereas PET–CT could clearly differentiate low from high-grade chon-
drosarcoma. We identified added utility of PET–CT in addition to MRI and CT in high-grade sarcoma of bone and soft 
tissues. An estimated 21% overall potential benefit was observed for PET–CT over CT/MRI, and in particular, in ‘upstag-
ing’ of high-grade disease (from M0 to M1) where an additional 12% of cases were deemed M1 following PET–CT.
Conclusions: PET–CT in high-grade bone and soft tissue sarcoma can add significant benefit to routine CT/MRI stag-
ing. Further prospective and multi-centre evaluation of PET–CT is warranted to determine the actual predictive value 
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Background
Conventional cross-sectional imaging techniques are 
routinely applied to the diagnostic and staging imag-
ing of bone and soft tissue sarcomas, e.g. CT and MRI 
[1–3]. Diagnostic review of biopsies and staging scans 
in supra-regional multi-disciplinary teams (MDT), aims 
to inform clinical management in line with national and 
international sarcoma guidelines. MRI is also generally 
performed to guide local staging and restaging follow-
ing neo-adjuvant therapy, whereas in subsequent post-
treatment follow-up, high resolution CT is primarily 
used for the detection of distant metastases, particularly 
in the lung. As primary curative treatment for sarcoma is 
mostly surgical, accurate staging is essential in order to 
minimize inappropriate interventions in the presence of 
metastatic disease.
Combined 18F-FDG Positron Emission Tomography 
with CT (PET–CT) offers potential advantages with 
respect to sarcoma, as it provides both metabolic and 
anatomical imaging combined in a single examination. 
Sarcomas are frequently large tumours (> 5  cm) with 
intra-tumour regional and cellular heterogeneity, and 
frequently in larger tumours, central necrosis associated 
with hypoxia. As mesenchymal derived cancers, sarco-
mas may be detected by 18FDG uptake because of the 
general high metabolic activity and insulin sensitivity of 
these tissues. The maximum standardized uptake value 
(SUVmax) of 18FDG into higher-grade sarcoma appears 
to correlate with mitotic count and grade in some 
reported series [4, 5], and potentially with overall prog-
nosis [6–10]. Reporting response assessment to oncologi-
cal therapies using SUVmax before and after treatment, 
may also better correlate with histological response com-
pared to dimensions alone [11]. With the advent of new 
systemic therapies that are either cytostatic or immune-
modulatory, PET–CT has additional potential advantages 
in assessing responses depending on the therapeutic 
mechanism.
Despite these potential advantages, there have been 
relatively few reported series, with low cases numbers, 
providing information on which to base the routine appli-
cation of functional PET–CT in specialist sarcoma clini-
cal practice [12–20]. Moreover, in rare (< 6 per 100,000 
population) sarcoma subtypes (approximately 80 differ-
ent molecular based diagnostic subtypes in the WHO 
classification 2013), there appears even less ‘real world’ 
reported evidence for the application of PET–CT. Here, 
we retrospectively audit consecutively performed PET–
CT scans in a supra-regional sarcoma centre. We initially 
attempted to address three questions; the correlation 
between histological sub-type and grade with 18FDG 
uptake; the use of PET–CT in the clinical setting of stag-
ing (during initial diagnosis), restaging (new baseline 
prior to definitive intervention) and treatment response, 
and the potential additional benefit obtained from PET–
CT over concurrent conventional CT and MRI imaging 
in these settings.
Methods
Patient database
Retrospective audit of consecutive 18FDG PET–CT scans 
from one supra-regional UK sarcoma centre (Multi-dis-
ciplinary team, Oxford Sarcoma Service, Oxford Univer-
sity Hospitals Foundation Trust, UK) occurred between 
1st February 2007 and 25th June 2014. The radiology 
search for scans was independently cross-referenced with 
the Oxford Sarcoma Service (OxSarc) sarcoma database 
(2006–2014) for diagnosis and outcome, to ensure that 
patients had been captured on both systems. The histo-
logical subtype and grade of each sarcoma was confirmed 
by pathology review and accessed via the local EPR sys-
tem. Grade I sarcoma were regarded as low-grade, and 
grade II and III sarcoma as high-grade. All imaging (MRI, 
CT and PET–CT) were performed as directed either by 
the MDT, or were performed just prior to referral by an 
external clinician, with the information obtained used for 
consensus MDT agreement for subsequent clinical man-
agement. Thus, all scans performed and reported here 
were approved by the MDT specialist sarcoma team, and 
were therefore driven either as a result of the initial his-
tology result of the biopsy, or appearances of local imag-
ing of the presenting mass etc.
Imaging procedures
PET–CT imaging from June 2007 to 2nd November 
2009 was performed on a GE Discovery (STE BGO 16 
slice CT, 400  MBq 18FDG, 60  min uptake period, fixed 
80 mA/140 kV for CT, 4 min per bed position) and from 
3rd November 2009, on a GE Discovery 690 (LYSO time 
of flight) 64 slice CT, 4  MBq/kg 18FDG, 90  min uptake 
period, modulated mA based on noise index (n = 25) 
120  kV, 4  min per bed position). All scans included the 
skull base to either the upper thigh, or at least the joint 
below primary disease in the lower limbs where required, 
and cost-effectiveness of PET–CT in directing clinical management of clinically complex and heterogeneous high-
grade sarcomas.
Keywords: Sarcoma, Positron emission tomography, Multi-disciplinary, Staging, Therapeutic response
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and included the head in skull or head and neck disease. 
Patients were fasted with a standard procedure for at 
least 6  h prior to the PET–CT. All the PET–CT exami-
nations were independently reported by two consult-
ant radiologists subspecializing in nuclear medicine and 
PET–CT, and were re-reviewed by a post CCT radiolo-
gist subspecializing in nuclear medicine/PET (RM) as 
part of this evaluation alongside the verified reports.
For the purpose of assessing the correlation between 
sarcoma grade and disease avidity, the FDG avidity cal-
culated as standardized uptake value (SUVmax) on each 
PET–CT was recorded. SUVmax is simply the decay cor-
rected maximum tracer activity (18FDG) within a volume 
of interest (VOI) and is available on all PET–CT scans. 
The standardized uptake value is (SUV) = [VOI activ-
ity concentration]/[injected activity/Weight g/mL], and 
if 1  mL of tissue volume is taken to weigh 1  g, then it 
becomes unit-less. The most FDG avid focus site of dis-
ease, whether primary or metastatic, was utilized as the 
SUVmax. In those cases where the SUVmax was not 
documented, this was re-calculated using standard GE 
supplied PET–CT analysis software. If there was CT evi-
dence of a disease site however, with the FDG uptake at 
or below background (mediastinal blood pool) levels i.e. 
sites that are FDG essentially negative, the FDG avidity 
was documented as equal to 1.
Imaging evaluation
All 18FDG PET–CT and conventional imaging modali-
ties (CT and MRI) were re-analyzed with respect to sar-
coma diagnostic sub-type, the timing and purpose of 
the scan with respect to staging, restaging or treatment 
response. The differences in sarcoma disease distribu-
tion between the 18FDG PET–CT and conventional MRI/
CT scans were documented if scans were performed 
within 4  weeks of each other, otherwise any differences 
were not reported for the purpose of this evaluation. Not 
all patients had all types of scan within 4 weeks of each 
other, and so comparisons are necessarily retrospective 
and cannot be formally evaluated beyond descriptive 
reporting. For bone and pulmonary metastatic sites that 
were identified by PET–CT, the non-contrast enhanced 
CT components of the scan were examined separately 
and considered as the ‘conventional’ CT imaging modal-
ity. For soft tissue sites, including abdominal and pelvic 
sites, comparisons were made between 18FDG PET–CT 
and either separate contrast enhanced CT scans or 
MRI scans where possible. The specific 18FDG PET–CT 
advantages over conventional imaging were also deter-
mined for occult and solitary disease in either visceral, 
bone, muscular, sub-cutaneous and nodal sites. Histopa-
thology was undertaken using standard diagnostic path-
way with UK sarcoma reference pathologist (NA), using 
conventional WHO international guidelines (2012) and 
French based staging system (FNCCC). For the assess-
ment of additional potential advantages of PET–CT, this 
was only conferred once histological data was reviewed 
to determine whether ‘PET positive’ disease had been 
histologically proven, or, if sampling had not been under-
taken, where there was imaging evidence of progression 
over time confirming the presence of malignant disease, 
except for the common incidental unrelated sites in the 
colon, thyroid, prostate and breast.
Statistical analysis
Descriptive statistics using Prism 7.0a were applied, 
including ANOVA and non-parametric Mann–Whitney 
tests. Sensitivity, specificity, positive predictive value and 
negative predictive values were calculated by standard 
means.
Results
Over the 7-year period of the audit evaluation, a total of 
493 patients (age range 15–91, median 55 years) referred 
to the Oxford MDT with histologically confirmed sar-
coma, underwent a total of 957 PET–CT scans during 
their course of management. The number of patients 
within sarcoma sub-types, the number of PET–CT stud-
ies performed and the clinical indications for performing 
PET–CT are shown (Table 1, Fig. 1). Most PET–CT scans 
were performed in high-grade (n = 930) versus low-grade 
sarcoma (n = 27, e.g. low grade chondrosarcoma and 
low grade soft tissue sarcoma), with a wide distribution 
of histological subtypes that reflect the distribution of 
referred cases (shown are where there were > 4 cases per 
histological subtype, Fig. 1). PET–CT scans were usually 
performed as a result of MDT decisions, usually in the 
context of patients that were being planned to undergo 
radical treatments, such as radical surgery, and where the 
scan was for initial staging and exclusion of metastatic 
disease (36% of scans). All of these cases had concurrent 
MRI and CT imaging already, mainly for local staging 
and exclusion of lung metastasis. In this staging popula-
tion, a further 12% (42/344) then had detectable meta-
static disease overall by PET–CT that was not detected 
by conventional CT/MRI. Re-staging with a new baseline 
scan occurred in cases with suspected later relapse, prior 
to potential further radical and salvage treatment (39% of 
scans), and assessment of treatment response to thera-
peutics in the remaining (35% of scans, see Table 1). 
A statistically significant difference was observed 
between mean SUVmax of high and of low-grade 
sarcoma independent of histological subtype (p 
value < 0.0001, Fig.  2). Most high-grade sarcomas had 
mean SUVmax values greater than 10, with wide distri-
bution of SUVmax activity rather than a defined cut-off, 
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Table 1 Number of patients, PET–CTs and indication for PET–CTs according to sarcoma subtype
DSRCT desmoplastic small round cell sarcoma, MPNST malignant peripheral nerve sheath tumour, includes low-grade
a Note this is overall detection of metastatic disease at initial CT and MRI staging only, ‘added value’ comparison is reported in Table 3
b Includes high grade ‘spindle cell sarcoma’
c Includes ‘high grade epitheloid haemangioendothelioma’
Sarcoma pathological diagnosis Number of patients Number of PET–CT scans
Total Staginga (with metastasis) Restaging Treatment response
Undifferentiated  pleomorphicb 81 166 64 (6) 62 40
Angiosarcomac 8 11 7 (1) 3 1
Leiomyosarcoma 89 166 43 (8) 84 39
Rhabdomyosarcoma 16 53 13 (4) 15 25
Myxofibrosarcoma 21 30 14 (2) 8 8
Epithelioid sarcoma 10 23 7 (1) 15 1
Osteosarcoma 48 98 39 (7) 28 31
Clear cell sarcoma 6 8 5 (1) 3 0
Ewing sarcoma/DSRCT 31 120 20 (6) 47 53
Synovial sarcoma 26 44 17 (3) 24 3
De-differentiated liposarcoma 18 36 11 (1) 17 8
Solitary fibrous tumour 14 25 8 (1) 9 8
Chondrosarcoma grade 2/3 24 45 18 (1) 17 10
Myxoid/round cell liposarcoma 26 36 18 (4) 12 6
Alveolar soft part sarcoma 4 4 4 (1) 0 0
MPNST 37 65 33 (4) 21 11
Low grade soft tissue sarcoma 25 17 17 (0) 0 0
Chondrosarcoma grade 1 9 10 6 (0) 4 0
Total 493 957 344 (51) 369 244
Fig. 1 Distribution of molecular-histological subtypes of the 493 sarcoma cases reported that underwent a 18F-FDG PET–CT between 2007 and 
2014. Following diagnostic biopsy (core needle or excision biopsy), the molecular and histological subtypes of sarcoma were identified. A total 
of 493 cases of sarcoma were diagnosed and were distributed into the following listed sub-types (minimum 4 cases per subtype, pie chart runs 
clockwise)
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making the distinction within grade and between his-
tological subtypes more subtle (Fig.  2). Importantly, 
between the specific low and high-grade subtypes, 
there appeared significant differences in SUVmax that 
presumably reflects the differential mechanisms of 
cellular derangement (Fig. 3a). For the example of chon-
drosarcoma, the differences between low and high-grade 
defined histologically also appeared to threshold at the 
SUVmax value of 4 (Fig.  3b), whereas in MPNST, the 
spectrum of SUVmax values significantly overlapped 
depending on the histological classification, making any 
distinction of grade based on SUVmax less discrimina-
tive and less correlative with histology (Fig. 3c). A further 
factor in relation to SUVmax distribution and histology 
also includes the anatomical origin of otherwise indenti-
cal histologies, exemplified by leiomyosarcoma, with an 
apparent higher SUVmax observed in gynaecological 
compared to non-gynaecological (vascular) origin leio-
myosarcoma (Fig. 3d).
As a result of intra-tumoural heterogeneity, differences 
in SUVmax between sarcoma sites within each patient 
may be manifest at different stages of the disease. SUV-
max values were compared between scans performed at 
primary staging, with those performed later in follow-up 
in relapse. The expectation was that more aggressive cell 
types would have populated relapse disease sites com-
pared to the primary tumour, and potentially be reflected 
in a higher SUVmax in those relapsed sites. Subsequent 
comparison of the highest SUVmax per scan at primary 
staging and restaging, grouped by sarcoma histological 
subtype, revealed no statistically significant differences 
(Figs. 4), although in some subtypes, trends in SUVmax 
values may be increasing, e.g. in leiomyosarcoma. 
Of the 930 PET–CT scans performed in high-grade 
sarcoma, 193 displayed features considered to have added 
value over conventional CT and/or MRI performed con-
currently (21%, Table  2). Of these 193 PET–CT scans, 
56 were performed at initial sarcoma diagnostic stag-
ing, 78 at re-staging (new baselines) and 59 in treatment 
(chemotherapy) responses (Table 2). Here, ‘added value’ 
refers to any additional specific features offered by PET–
CT. Specifically, added value does not only relate to the 
Fig. 2 Distribution of the highest SUVmax values per 18F-FDG PET–CT from each of 957 scans within each sarcoma diagnostic sub-type. For each 
PET–CT scan performed in each histological sub-type listed, the highest SUVmax values were collated and distributions determined. A minimum of 
4 cases per-subtype. Mean (symbol) and 95% confidence intervals are shown in rank order
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identification of further metastatic disease sites in addi-
tion to those already identified by the conventional CT 
and MRI imaging, but to those features resulting in so-
called ‘upstaging’ of disease. For example, PET–CT spe-
cific detection of either occult muscular and soft tissue 
metastases, small peritoneal or other visceral metastases 
not visualized by conventional non-contrast enhanced 
CT (as part of PET–CT) and MRI imaging (Table  3, 
see examples in Fig.  5). Thus, ‘added value’ of PET–CT 
reflects detection of metastatic disease (M1) in patients 
who would be otherwise staged as M0 by conventional 
imaging approaches. In patients with high-grade sar-
coma, it was possible to compare a total of 284 PET–CT 
scans with the conventional CT and MRI specifically dur-
ing the initial diagnostic staging. In terms of the pres-
ence or absence of metastatic disease (M0 versus M1), 
of these, 232 patients were true negatives for metastatic 
disease (negative in both PET–CT and the conventional 
imaging), 24 were true positive (positive in both PET–CT 
and the conventional imaging), 23 were false negatives 
(positively identified disease in PET–CT) and 1 was a 
false positive (non-disease associated FDG uptake). This 
retrospective data results in an overall metastatic disease 
rate of 10% based on conventional CT and MRI, and 22% 
for detection with dual modality PET–CT. As both CT 
and PET should both be able to detect the predominant 
sites of pulmonary metastatic disease, this additional 
benefit might be expected to be mainly because of detec-
tion of non-pulmonary metastatic disease sites. Follow-
ing scrutiny of these staging PET–CTs, ‘added value’ was 
indeed associated with detection of occult metastatic 
sites in bone, muscle and visceral sites, accounting for the 
Fig. 3 The distributions of the highest SUVmax values per 18F-FDG PET–CT scan with respect to examples of sarcoma cases defined histologically as 
low and high-grade. a The highest SUVmax values in each of 957 PET–CT scans are shown with respect to histologically low-or high-grade sarcoma 
(e.g. low-grade soft tissue sarcoma, chondrosarcoma, MPNST). Note the overlap of SUVmax values between high and low-grade sarcoma in the 
range of SUVmax values of 4-8 (dashed line at 5). Specific comparison of SUVmax values between; b high and low-grade chondrosarcoma, c high 
and low-grade malignant peripheral nerve sheath tumours, and d leiomyosarcoma arising from gynaecological (uterine) versus non-gynaecological 
origin
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PET–CT upstaging (Table  3). Overall, given the preva-
lence of sarcoma sub-types in this bone and soft tissue 
sarcoma series, and compared to conventional MRI/CT, 
PET–CT appeared to have a greater sensitivity (96% vs 
54%), positive predictive value (96%) and negative predic-
tive value (99%), even though these sensitivity and speci-
ficity values were not prospectively evaluated. 
Moreover, ‘added value’ also relates to altered FDG 
avidity in static sized lesions, either indicating increased 
SUVmax suggesting disease presence or progression, 
and decreased SUVmax, as a reflection of responses to 
oncological treatment. In this context, PET–CT specifi-
cally might have ‘added value’ in the characterization of 
enlarged FDG negative loco-regional lymph nodes that 
are likely reactive rather than sarcoma containing, and in 
the detection of FDG avid lesions near prostheses follow-
ing reconstructive surgery, where MRI and CT artifacts 
preclude accurate assessment (Table  3). These findings 
overall are therefore relevant both to achieving accurate 
TNM staging, but also to directly influence clinical deci-
sion-making for subsequent radical surgical, radiother-
apy and chemotherapy interventions.
In terms of histological sub-types, the highest over-
all ‘added value’ appeared in the context of malig-
nant peripheral nerve sheath tumour subtype of sarcoma 
(41.6%), whereas in most cases of myxofibrosarcoma 
and solitary fibrous tumour, the advantages of PET–CT 
were manifest during follow-up re-staging and treat-
ment response assessment (Table 2). For chemo-sensitive 
sarcoma, ‘added value’ was skewed towards the chemo-
therapy treatment response assessment scans (e.g. in 
chemotherapy responsive rhabdomyosarcoma and Ewing 
sarcoma), and following trabectedin chemotherapy, such 
as in leiomyosarcoma (Table 2) [21]. For diagnostic stag-
ing and re-staging, significant ‘added value’ reasons also 
included identification of local recurrence sites at and 
Fig. 4 Distribution of the highest SUVmax values from each of 957 18F-FDG PET–CT scans within each sarcoma diagnostic sub-type in the primary 
lesion and following relapse (re-staging after primary treatment). High-grade sarcoma can have a propensity to relapse after primary (baseline) 
treatment (e.g. after surgery, radiotherapy and chemotherapy). The figure shows a comparison of the distribution of the highest SUVmax values per 
scan within subtypes, where there were also SUVmax values at relapse. The mean and 95% confidence intervals show non-significant differences 
(Non-parametric Mann–Whitney), but are suggestive of potential selection for higher-grade clones (higher SUVmax and altered confidence interval 
range) in relapse
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near prostheses (18/138), during the follow up of FDG 
positive lesions (17/138), for all lesions missed (not eas-
ily visible) by conventional imaging (16/138), for intra-
lesional heterogeneity to guide diagnostic biopsies 
(16/138), and for occult (not previously visible) bone 
metastasis (13/138).
Discussion
Here we report a retrospective audit and evaluation 
of PET–CT clinical use in a single tertiary UK sarcoma 
center. The data represents one of the largest reported 
series of PET–CT use in routine sarcoma clinical prac-
tice, but this does not represent a definitive, prospective, 
clinical and cost effective evaluation. Despite these cave-
ats, the use of PET–CT in this report does appear in line 
with evolving guidelines, including the most recent 2016 
Royal College of Radiologists, UK guidelines for PET–CT 
in sarcoma [22]. As such, it provides valuable preliminary 
evidence on which to base future multi-center evaluation 
in a routine clinical practice, as a clinical research tool, 
and in the development of evidence suitable for support-
ing appropriate reimbursement.
In sarcoma, oncogenic drivers frequently result in up-
regulation of glucose transporters, such as GLUT4 [23], 
resulting in higher 18FDG SUVmax levels associated with 
aggressive cell behavior, and when there is associated 
immune cell infiltration, such as in giant cell tumour of 
bone [24]. As expected, we observed statistically signifi-
cant differences of mean SUVmax between low-grade 
and high-grade sarcoma histological sub-types. More-
over, significant variation in SUVmax was observed 
between different patients who had the same sarcoma 
Fig. 5 Examples of 18F-FDG PET and fused PET–CT images with added value detection of disease sites in sarcoma. All images are on an SUV scale 
of 0–6. a Case of a 57 year-old female with hilar lung metastatic leiomyosarcoma, but with occult metastatic sites (arrows; right buttock and left 
para-aortic region) not clearly evident on conventional CT scans. b Case of a 54 year-old female with undifferentiated pleomorphic sarcoma (UPS) 
with primary right axillary disease, but with an occult bone secondary in the pelvis (arrow) on PET–CT. c Case of a 23 year-old male with distal femur 
osteosarcoma post MAP chemotherapy (pre-op) and after reconstructive surgery and prosthetic replacement with a local recurrence (post-op). 
Arrow indicates FDG avid nodule of local recurrence close to the prosthetic margin not visible on CT
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sub-type. The latter probably reflects the functional het-
erogeneity within the tumour and its associated micro-
environment, indicating that between sarcoma subtypes, 
primary and metastatic disease, there are differences in 
SUVmax that reflect those at the molecular, cellular and 
micro-environment level. PET–CT appeared useful in 
identifying sarcoma sites that contained both high and 
low- grade elements (the extremes of heterogeneity), for 
example in de-differentiated liposarcoma, de-differenti-
ated chondrosarcoma and in MPNST. SUVmax values > 5 
were consistent with higher-grade disease, except in the 
case of MPNST, where there was much less correlation 
of SUVmax with histological assessment of grade. Thus, 
low-grade soft tissue sarcoma and low-grade bone sar-
coma (e.g. chondrosarcoma) do not probably warrant 
routine PET–CT estaging valuation, unless there is clini-
cal suspicion of high-grade transformation, such as in 
either large axial or pelvic chondrosarcoma.
The additional benefits (“added value”) of PET–CT 
appeared to be in a range of clinical contexts, making 
specific comparisons and overall evaluation more com-
plex. Here we attempted to simply compare conven-
tional CT and MRI scans performed concurrently with 
the PET–CT, in order to scope the scenarios that might 
justify PET–CT as a routine dual scanning modality, 
and that impacts on potentially clinically important fea-
tures. What we have not been able to fully assess in all 
circumstances, is to prospectively prove that direct and 
important changes to subsequent clinical management 
of patients ensued as a result of the PET–CT results, and 
the PET–CT results alone. For example, there can be no 
doubt from the radiological and clinical point of view, 
that the ‘added value’ of PET–CT in upstaging of dis-
ease from M0 to M1 would have had clinical impact that 
might make the difference between either reconstructing 
a limb, resecting a tumour or amputation. In this regard, 
our evidence suggests that whole body PET–CT has par-
ticular utility in detection of occult non-pulmonary dis-
ease not visible on conventional CT and MRI. As both 
CT and PET should both be able to detect the predomi-
nant sites of pulmonary metastatic disease, scrutiny of 
these staging PET–CTs for ‘added value’ was indeed asso-
ciated with detection of occult metastatic sites in bone, 
muscle and visceral sites, accounting for the PET–CT 
upstaging. Moreover, ‘added value’ to guiding biopsies 
to active and viable areas of the tumour, thereby avoid-
ing regions of necrosis, and in the post-operative setting, 
where MRI artifacts near metallic prostheses prevents 
Table 2 Number of PET–CTs in which ‘added value’ was detected compared to conventional imaging (MRI/CT) according 
to sarcoma subtype
DSRCT desmoplastic small round cell sarcoma, MPNST malignant peripheral nerve sheath tumour, includes low-grade
a Includes high grade ‘spindle cell sarcoma’
b Includes ‘high grade epitheloid haemangioendothelioma’
Sarcoma pathological diagnosis Percentage of PET–CT with added value Number of PET–CT with added value over MRI/CT
Staging Restaging Treatment response
Undifferentiated  pleomorphica 13.3% (22/166) 6 11 5
Angiosarcomab 9% (1/11) 1 0 0
Leiomyosarcoma 18% (30/166) 7 14 9
Rhabdomyosarcoma 24.6% (13/53) 3 2 8
Myxofibrosarcoma 26.7% (8/30) 0 5 3
Epithelioid sarcoma 13% (3/23) 1 2 0
Osteosarcoma 23.5% (23/98) 6 9 8
Clear cell sarcoma 12.5% (1/8) 1 0 0
Ewing sarcoma/DSRCT 27.5% (33/120) 7 12 14
Synovial sarcoma 13.6% (6/44) 3 2 1
De-differentiated liposarcoma 8.3% (3/36) 1 1 1
Solitary fibrous tumour 28% (7/25) 0 5 2
Chondrosarcoma grade 2/3 24.4% (11/45) 3 5 3
Myxoid/round cell liposarcoma 11.1% (4/36) 2 1 1
Alveolar soft part sarcoma 25% (1/4) 1 0 0
MPNST 41.6% (27/65) 14 9 4
Low grade soft tissue sarcoma 0% (0/17) 0 0 0
Chondrosarcoma grade 1 0% (0/10) 0 0 0
Total 21% (193/930) 56 78 59
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adequate visualization of potential local recurrence, are 
also bona fide reasons to adopt PET–CT [8, 25, 26]. Con-
versely, inflammation related 18FDG avid foci in PET–CT 
studies immediately following surgery, chemotherapy 
and radiotherapy, can be mistaken for tumour deposits, 
and can be miss-interpreted by inexperienced reporting, 
resulting in false positives.
The choice of imaging is therefore a significant con-
sideration when determining the timing of assessment, 
and may bias the subsequent reporting of results in this 
study. In the treatment response assessment, PET–CT 
addresses the discrepancy between the change in lesion 
size and metabolic response, and was the common-
est reason for “added value” of PET–CT over conven-
tional imaging in our series. In the staging and re-staging 
groups, occult metastatic disease and FDG avid nodal 
disease, which were not enlarged by CT criteria, may 
have led to improved TNM staging accuracy overall. 
Likewise, the presence of new sites of disease (occult 
disease) in the standardized dimension assessment of 
oncological treatment response, also indicates the need 
to stop current treatment and to re-evaluate alternative 
strategies. Whilst the staging and later findings related to 
‘added value’ are based on comparison of imaging modal-
ities performed within a few weeks, and whilst some 
sarcomas may rapidly grow over such a time frame, these 
cases are very rare, and so we believe that the comparison 
period is valid.
The heterogeneity of the behavior of sarcoma cells 
points to the potential for high-grade cell types with 
more aggressive features to populate recurrent sites of 
disease detected at restaging. SUVmax alone does not, 
however, constitute a complete analysis of heterogene-
ity, and this question requires further analyses, as the 
overall 18FDG distribution within tumours has not been 
assessed. Further prospective validation of PET–CT in 
sarcoma is justified, as ‘added value’ components may 
also reflect differences in reporting experience and pro-
tocols. To eliminate future bias, the prospective evalua-
tion of conventional imaging compared with PET–CT 
across institutions will require standardized reporting 
(independent double blind reporting) for both modali-
ties. Moreover, quantification of patient outcomes with 
respect to changes in clinical management would need 
to be prospectively compared, as well as staging accuracy 
and cost effectiveness for the patient pathway. In sum-
mary, PET–CT in high-grade sarcoma offers the prospect 
additional benefit in routine staging of high-grade sar-
coma at baseline, and specific staging situations during 
relapse and treatment.
Table 3 Summary of the ‘added value’ features of PET–CT compared to conventional imaging (MRI and CT)
a Restaging = new baseline imaging prior to new clinical management intervention
b Actual number of M0 to M1 upstaging = 25
Reasons for added value of PET–CT over conventional imaging Number of PET–CT scans per indication
Stagingb Restaginga Treatment response
Occult bone metastases 10 3 1
Recurrence at local site or adjacent to metallic prosthesis not definitive on conventional imaging 0 18 2
Follow up of occult bone metastases 0 8 10
Occult muscular metastases 3 0 0
Follow up of occult muscular metastases 0 3 2
Cardiac metastases (muscular) not detected on conventional imaging 2 1 0
Subcentimetre FDG avid nodes 5 2 1
Static tumoural size, reduced FDG avidity 0 7 16
Static tumoural size, increased FDG avidity 6 2 6
Solitary FDG avid pulmonary nodule, indeterminate on CT 7 3 0
Missed visceral disease on CT/MRI 11 5 5
Metastasis outside the fields of conventional imaging 1 0 0
FDG negative suspected recurrence adjacent to prosthesis or locally in patient with prior markedly 
avid disease
0 3 2
Intra-lesional heterogeneity—guided biopsy to avoid underestimation of grade 10 6 0
Enlarged FDG negative nodes with moderately FDG avid primary 1 2 0
Increase in tumoural size but reduced avidity 0 0 7
Recurrence at an ablation or surgical site, indeterminate on MRI 0 2 0
Follow up of FDG positive disease adjacent to prosthesis or local surgical site 0 13 7
Total 56 78 59
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Conclusion
We report a large retrospective audit of PET–CT in 
bone and soft tissue sarcoma with varied grade in a sin-
gle multi-disciplinary centre. A total of 957 consecutive 
PET–CT scans were performed in a single supra-regional 
centre in 493 sarcoma patients (excluding GIST) between 
2007 and 2014. High-grade (II/III) bone and soft tis-
sue sarcoma correlated with high SUVmax, especially 
undifferentiated pleomorphic sarcoma, leiomyosarcoma, 
translocation induced sarcomas (Ewing, synovial, alveo-
lar rhabdomyosarcoma), de-differentiated liposarcoma 
and osteosarcoma. We identified added utility of PET–
CT in addition to MRI and CT in high-grade sarcoma of 
bone and soft tissues. An estimated 21% overall potential 
benefit was observed for PET–CT over CT/MRI, and in 
particular, in ‘upstaging’ of high-grade disease (from M0 
to M1) where an additional 12% of cases were deemed 
M1 following PET–CT. This large study suggests PET–
CT in high-grade bone and soft tissue sarcoma can add 
significant benefit to routine CT/MRI staging. Further 
prospective and multi-centre evaluation of PET–CT is 
warranted to determine the actual predictive value and 
cost-effectiveness of PET–CT in directing clinical man-
agement of clinically complex and heterogeneous high-
grade sarcomas.
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